epilepticme
09-06-2008, 05:55 PM
Cannabis, pain, and sleep (what the Labour Party dont want you to know)
submit a free press release - PR.Canna Zine - Cannabis, pain, and sleep (what the Labour Party dont want you to know) (http://pr.cannazine.co.uk/content/view/612/27/)
Back in 2007 MS patients all over the world waited with bated breath, for news of a new wonder drug which is extracted from the cannabis plant.
Patient trials went well, with the great majority of people showing a positive reaction to the cannabis treatment and yet today in 2008, people are still suffering in silence waiting for a safe drug to be delivered, and in the meantime pharmaceutical drugs which have already run the vigorous procedure which leads to public licensing are being withdrawn daily, as it turns out they can induce strokes in people?
Lessons from therapeutic clinical trials of Sativex.
Originally published by GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wiltshire SP4OJQ, UK. [email protected] e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Cannabis sativa L. has been utilized for treatment of pain and sleep disorders since ancient times. This review examines modern studies on effects of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep.
It goes on to report new information on the effects on sleep in the context of medical treatment of neuropathic pain and symptoms of multiple sclerosis (http://multiplesclerosis.researchtoday.net/), employing standardized oromucosal cannabis-based medicines containing primarily THC, CBD, or a 1 : 1 combination of the two (Sativex).
Sleep-laboratory results indicate a mild activating effect of CBD, and slight residual sedation with THC-predominant extracts.Experience to date with Sativex in numerous Phase I-III studies in 2000 subjects with 1000 patient years of exposure demonstrate marked improvement in subjective sleep parameters in patients with a wide variety of pain conditions including multiple sclerosis (http://multiplesclerosis.researchtoday.net/), peripheral neuropathic pain, intractable cancer pain, and rheumatoid arthritis (http://rheumatoidarthritis.researchtoday.net/), with an acceptable adverse event profile.
No tolerance to the benefit of Sativex on pain or sleep, nor need for dosage increases have been noted in safety extension studies of up to four years, wherein 40-50% of subjects attained good or very good sleep quality, a key source of disability in chronic pain syndromes that may contribute to patients' quality of life.
Published 27 August 2007 in Chem Biodivers, 4(8): 1729-43.
Full-text of this article is available online (http://dx.doi.org/10.1002/cbdv.200790150) (may require subscription).
submit a free press release - PR.Canna Zine - Cannabis, pain, and sleep (what the Labour Party dont want you to know) (http://pr.cannazine.co.uk/content/view/612/27/)
Back in 2007 MS patients all over the world waited with bated breath, for news of a new wonder drug which is extracted from the cannabis plant.
Patient trials went well, with the great majority of people showing a positive reaction to the cannabis treatment and yet today in 2008, people are still suffering in silence waiting for a safe drug to be delivered, and in the meantime pharmaceutical drugs which have already run the vigorous procedure which leads to public licensing are being withdrawn daily, as it turns out they can induce strokes in people?
Lessons from therapeutic clinical trials of Sativex.
Originally published by GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wiltshire SP4OJQ, UK. [email protected] e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Cannabis sativa L. has been utilized for treatment of pain and sleep disorders since ancient times. This review examines modern studies on effects of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep.
It goes on to report new information on the effects on sleep in the context of medical treatment of neuropathic pain and symptoms of multiple sclerosis (http://multiplesclerosis.researchtoday.net/), employing standardized oromucosal cannabis-based medicines containing primarily THC, CBD, or a 1 : 1 combination of the two (Sativex).
Sleep-laboratory results indicate a mild activating effect of CBD, and slight residual sedation with THC-predominant extracts.Experience to date with Sativex in numerous Phase I-III studies in 2000 subjects with 1000 patient years of exposure demonstrate marked improvement in subjective sleep parameters in patients with a wide variety of pain conditions including multiple sclerosis (http://multiplesclerosis.researchtoday.net/), peripheral neuropathic pain, intractable cancer pain, and rheumatoid arthritis (http://rheumatoidarthritis.researchtoday.net/), with an acceptable adverse event profile.
No tolerance to the benefit of Sativex on pain or sleep, nor need for dosage increases have been noted in safety extension studies of up to four years, wherein 40-50% of subjects attained good or very good sleep quality, a key source of disability in chronic pain syndromes that may contribute to patients' quality of life.
Published 27 August 2007 in Chem Biodivers, 4(8): 1729-43.
Full-text of this article is available online (http://dx.doi.org/10.1002/cbdv.200790150) (may require subscription).